JPRN-jRCT2071200096招募中2 期
A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia
Tanaka Yoshiyuki0 个研究点目标入组 40 人开始时间: 2021年2月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 50age old（—）
- 性别
- All
入选标准
- •Meet the diagnostic criteria for schizophrenia according to the DSM-5
- •- Have an illness duration for schizophrenia of at least 1 year and <=15 years
- •- Be confirmed to be experiencing an acute episode of schizophrenia as evidenced by ALL of the following: (a) onset of the current acute episode is <=4 weeks prior to screening (b) current symptoms represent a marked and substantial worsening compared with the participant's usual symptomatic state prior to the current acute episode, and are associated with diminished functional ability (c) in need of increased psychiatric attention to treat worsening acute episode symptoms
- •- Have a CGI-S score of =>4 (moderately ill) at screening and baseline
- •- Have an identified responsible person referred to as the external contact person who has agreed to provide information about the participant's location if needed during outpatient portion of the study. The site personnel must consider this identified responsible person a reliable contact person, and the contact person must have regular contact with the participant (defined at screening as direct contact no fewer than 3 times per week), and with the expectation that this frequency of contact would continue (either in person or via other contact method), throughout duration of the study, including the follow-up period)
排除标准
- •- Has a primary current diagnosis other than schizophrenia or a comorbid diagnosis that is primarily responsible for the current symptoms and functional impairment
- •- Meets criteria for moderate to severe substance use disorder within past 6 months prior to screening (excluding those related to caffeine or nicotine)
- •- Has a known history of the following: (a) borderline personality disorder, anti-social personality disorder, or bipolar disorder (b) traumatic brain injury causing ongoing cognitive difficulties, Alzheimer's disease, or another form of dementia, or any chronic organic disease of the central nervous system (c) intellectual disability of a severity that would impact ability to participate in the study
- •- Has a current diagnosis of a psychotic disorder other than schizophrenia or a behavioral disturbance thought to be due to substance abuse
- •- Is or was under involuntary commitment for the acute episode, because the participant is considered a danger to themselves or others
- •- Has a history of treatment resistance exhibited by any of the following: (a) no or minimal response to at least 2 periods of treatment lasting 6 weeks or longer, with antipsychotic agents at the maximally tolerated dose. Participants who have responded to antipsychotics only when paired with clozapine are considered treatment resistant (b) history of electroconvulsive therapy (ECT) treatment for treatment resistant schizophrenia within the past 5 years (c) past or current use of clozapine as single or adjunctive therapy for schizophrenia within the past 5 years
- •- Is currently participating in or has participated in an interventional clinical research study within 12 months prior to the screening visit of this current study
研究者
相似试验
进行中（未招募）
1 期
A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of SchizophreniaMedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2020-000094-24-HRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.576
进行中（未招募）
1 期
A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of SchizophreniaMedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2020-000094-24-LVMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.576
进行中（未招募）
1 期
A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of SchizophreniaMedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2020-000094-24-BGMerck Sharp & Dohme LLC500
进行中（未招募）
1 期
A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of SchizophreniaMedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2020-000094-24-PLMerck Sharp & Dohme LLC500
进行中（未招募）
不适用
A Phase IIb Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy and Safety of Apomorphine Inhalation Powder in Patients With ?On-Off? or ?Wearing-Off? Effects Associated With Parkinson?s Disease - NDMedDRA version: 9.1Level: HLGTClassification code 10028037Parkinson?s deseaseMedDRA version: 9.1Level: PTClassification code 10030312EUCTR2008-004447-11-ITVECTURA LIMITED66